NRG258随机III期试验长期随访与总生存:局部晚期子宫内膜癌放化疗对比化疗
NRG258是一项随机III期试验,纳入813例局部晚期子宫内膜癌患者,比较顺铂联合容积放疗后卡铂+紫杉醇4周期(放化疗)与卡铂+紫杉醇6周期(化疗)的疗效。中位随访112个月,两组中位总生存均未达到,放化疗对比化疗的死亡分层风险比为1.05(95%CI 0.82-1.34,P=0.72),放化疗未改善无复发生存或总生存。
要点
- 放化疗对比化疗的死亡分层HR为1.05(95%CI 0.82-1.34,P=0.72),无总生存获益。
- 放化疗较化疗降低局部复发率,但未改善无复发生存或总生存。
- 所分析因素均未预测放化疗的总生存获益。
核心结论
- 放化疗虽较化疗降低局部复发率,但在III/IVA期子宫内膜癌中未改善无复发生存或总生存。
研究设计与样本
- 随机III期试验,纳入813例患者,随机分为放化疗组407例和化疗组406例。
- 入组标准为FIGO 2009 III-IVA期子宫内膜癌,或I/II期浆液性或透明细胞癌且细胞学阳性。
- 主要终点为无复发生存,次要终点为总生存、毒性和生活质量。
- 总生存累积概率采用Kaplan-Meier法估计,并按FIGO分期、年龄、种族、肉眼残留病灶、组织学、淋巴血管间隙浸润和体重指数进行亚组分析。
主要发现
- 中位随访112个月,两组中位总生存均未达到。
- 放化疗对比化疗的死亡分层风险比为1.05(95%CI 0.82-1.34,双侧对数秩P=0.72)。
- 所分析因素均未预测放化疗的总生存获益。
- 放化疗较化疗降低局部复发率,但未改善总生存或无复发生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This randomized phase III trial aimed to determine whether treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for four cycles (chemoradiotherapy [C-RT]) increased recurrence-free survival (RFS) and overall survival (OS) when compared with carboplatin and paclitaxel for six cycles (chemotherapy [CT]) in locally advanced endometrial cancer (UC). Previously reported results showed that C-RT did not improve RFS compared with CT. Here we report the final OS analysis. Patients with International Federation of Gynecology and Obstetrics (FIGO) 2009 stage III-IVA UC or stage I/II serous or clear cell UC and positive cytology were enrolled. The primary objective was RFS. Secondary objectives were OS, toxicity, and quality of life. Cumulative probabilities of OS were estimated using the Kaplan-Meier method. Subgroup analyses of treatment effect for FIGO stage, age, race, gross residual disease, histology, lymph-vascular space invasion, and body mass index were performed. In total, 813 patients were randomly assigned (407 C-RT and 406 CT). The median follow-up was 112 months. Median OS was not achieved in either arm. The stratified hazard ratio for death comparing C-RT versus CT was 1.05 (95% CI, 0.82 to 1.34, log-rank two-sided P value = .72). None of the factors analyzed predicted OS benefit from C-RT. Although C-RT reduced the rate of local recurrence compared with CT, it did not increase OS or RFS in stage III/IVA UC.
引用
- Matei DE, Enserro DM, Randall ME, et al. Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma. J Clin Oncol. 2024. PMID: 39700442. doi:10.1200/JCO.24.01121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。